Bertrand Tombal, Chairman Department of Surgery at Cliniques universitaires Saint-Luc, shared on LinkedIn:
“Proud to share our latest paper describing the design of the EORTC 2238 DE-ESCALATE trial, an international pragmatic phase III study evaluating whether intermittent maximal androgen blockade can safely reduce treatment burden while maintaining outcomes in men with mHSPC.
With modern AR pathway inhibitors, patients often receive treatment until progression. DE-ESCALATE revisits an important question: can selected patients with a deep PSA response safely benefit from treatment interruptions, potentially improving quality of life while preserving survival?
Congratulations to all investigators, patients, and partners involved in this truly European collaboration.”
Title: EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer
Authors: Guillaume Grisay, Fabio Turco, Anna Patrikidou, Enrique Gallardo, Ray McDermott, Erik Briers, Beatrice Fournier, Olga Basova, Bert Dhont, Marcell Csanádi, Silke Gillessen, Bertrand Tombal
Read also “Phase 3 ARANOTE Trial: Darolutamide Plus ADT in Black Patients With Metastatic Hormone-Sensitive Prostate Cancer” on OncoDaily.
